Page 1,228«..1020..1,2271,2281,2291,230..1,2401,250..»

Animal Stem Cell Therapy Market Poised to Expand at a Robust Pace Over 2017 2025 – Downey Magazine

Posted: December 17, 2019 at 3:45 am

Assessment of the Animal Stem Cell Therapy Market

The latest report on the Animal Stem Cell Therapy Market published by Persistence Market Research (PMR) is a valuable tool for established and upcoming market players to solidify their presence in Animal Stem Cell Therapy Market landscape. Further, by leveraging the real-time and result-driven insights included in the report, readers can formulate effective business strategies to gain an advantage in the competitive nature of the market.

The presented study suggests that the Animal Stem Cell Therapy Market is expected to attain a value of ~US$ XX by the end of assessment period and grow at a CAGR of ~XX% during the forecast period, 2017 2025. The underlying trends, growth opportunities, market drivers, and challenges faced by companies in the Animal Stem Cell Therapy Market are analyzed in detail.

Exciting Prices for New Customers!!!Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.persistencemarketresearch.co/samples/14941

Vital Information Included in the Report:

The competitive landscape chapter of the report provides valuable insights related to the business prospects of some of the leading companies in the Animal Stem Cell Therapy Market. The product portfolio, pricing structure, revenue growth, and footprint analysis of each market players are included in the report.

Important Queries Related to the Animal Stem Cell Therapy Market Addressed in the Report

The dynamics of the Animal Stem Cell Therapy Market across major geographical regions are included in the report and represented in the study. In addition, to provide a frictionless reading experience the data is depicted using informative graphs and other graphical illustrations.

Get Access To TOC Covering 200+ Topics at https://www.persistencemarketresearch.co/toc/14941

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

Request Customized Report As Per Your Requirements athttps://www.persistencemarketresearch.co/request-customization/14941

What Makes PMR Different?

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

305 Broadway, 7th FloorNew York City, NY 10007United StatesPh.no. +1-646-568-7751E-mail id- [emailprotected]Website: http://www.persistencemarketresearch.com

This post was originally published on Downey Magazine

View post:
Animal Stem Cell Therapy Market Poised to Expand at a Robust Pace Over 2017 2025 - Downey Magazine

Posted in Stem Cell Therapy | Comments Off on Animal Stem Cell Therapy Market Poised to Expand at a Robust Pace Over 2017 2025 – Downey Magazine

Robotics Industry Insights – Cobots, Raising the Human… – Robotics Online – Robotics Online

Posted: December 17, 2019 at 3:44 am

by Tanya M. Anandan, Contributing Editor Robotic Industries Association Posted 12/16/2019

Collaborative robotics is more than one kind of robot. It often involves a human working alongside a robot, and the collaborative robot (or cobot) is usually fenceless, but not always. They can have one arm, two arms, or none at all. They can be mobile or portable, small or large. They can work alone or as a fleet. Even standard industrial robots are fair game, thanks to innovations like FreeMove.

Last month we set out to broaden your view of human-robot interaction and collaboration. Were back to do it again. Well show how robots tackle labor shortages, reduce costs and optimize floor space. How they elevate the jobs humans do while improving process efficiency.

From making floral bouquets to inspecting bumpers, and bagging this seasons hottest tech toys, cobots are transforming the human-robot paradigm and knocking down barriers on the shop floor, between entire industries, and on a global scale.

Bumper-to-Bumper CobotsTier 1 automotive supplier Flex-N-Gate Corporation puts collaborative robots to work on the assembly line inspecting bumpers and other fascia components. These camera-wielding cobots use machine vision to inspect assembled components for proper orientation and installation. The robots work alongside their human coworkers without safety cages or other hard guarding to separate man from machine.

The Urbana, Illinois-based company supplies bumpers, exterior trim, lighting, chassis assemblies, and other automotive products. At the suppliers Ionia, Michigan facility, they stamp and assemble steel bumpers for the Ford Ranger pickup truck, among other vehicle platforms. Here, cobots inspect parts in two different assembly areas.

We supply a full bumper assembly module delivered directly to assembly plants, explains Nick Wiegand, Director of Advanced Manufacturing Global Metals and Assembly Group at Flex-N-Gate. We fabricate the steel shells via a progressive stamping process. The steel shells are then either painted, or chrome plated, or in some cases powder coated. Then we have other components that have to be affixed to the bumper, including internal structural components, fasteners, air dams, fog lamps, bezels, front parking assist (FPA) sensors, rear parking assist (RPA) sensors, blind-spot warning (BSW) sensors, integrated wiring harnesses, active air dams/grille shutters, and myriad other plastic and composite finishing accessories.

The amount of electronics that go into a bumper assembly these days is mind-boggling, says Wiegand. Were utilizing camera-carrying cobots in our assembly processes to ensure we have the right color/style combinations, and that all the requisite components based on the part recipe are present and installed correctly.

In one area of the shop floor, workers load a steel bumper onto a fixture in front of a green cobot arm. The FANUC CR-7 collaborative robot outfitted with a Cognex camera and integrated lighting swoops across the part inspecting and error-proofing assembled components. While the robot does its job, the operator can be tending to other areas of the assembly module.

On the moving assembly line, inverted FANUC cobots mounted just above the line workers heads maneuver at different angles, examining parts as they advance down the line. Watch Flex-N-Gates camera-wielding cobots at work.

Our biggest challenge was programming the cobots for line tracking, says Wiegand. Flex-N-Gate was the first in the industry to attempt this feat. We worked with the robot supplier and system integrator to solve issues as they arose.

Cost SavingsAutomated inspection has evolved at Flex-N-Gate. Traditionally, error proofing was done with a bank of overhead cameras, but this approach had its limitations. Fixed cameras made it difficult to see parts at optimal angles for the vision systems to read accurately and repeatedly. Company engineers had a better idea.

Why dont we put a camera at the end of a robot arm and take the camera to the inspection instead? says Wiegand. That was phase one in our evolution.

They mounted a camera on a conventional robot arm. Now they were able to position the camera in ideal locations for inspection and view aspects of parts they couldnt see before. Now they only had one camera to maintain instead of up to a dozen fixed cameras.

Wiegand says some of these cameras can range from $10,000 to $15,000 a piece, so the savings were significant. The next phase in their evolution deploying cobots would further reduce costs.

Space SavingsFlex-N-Gate was performing vision inspection with conventional high-speed, low-payload robots for about a year. Meanwhile, collaborative power and force limiting robots were garnering more attention as their applications grew, setting the stage for the suppliers transition to inspection with collaborative robots.

We were doing this with traditional robots, which required them to be caged and guarded per the RIA safety standards, just like you would any other industrial robot, says Wiegand. Were now able to do the exact same thing with collaborative robots and eliminate all of the guarding and a majority of the safety-related hardware costs. Now an operator can actually work beside the robot in that same station, enabling human work and robotic vision inspection simultaneously.

This collaborative robot cell not only saves costs associated with guarding and required safety devices and interlocks, but it also saves the floor space often required for fenced robot cells.

Inverted collaborative robots inspect automotive components alongside assembly line workers without requiring hard safety fencing. (Courtesy FANUC America Corporation)

Safety FirstThere are different ways to achieve a collaborative robotics application, as explained in Testing Thresholds for Collaborative Robot Safety and evidenced on the bumper assembly line. Besides the inherently collaborative nature of power and force limiting robots, Flex-N-Gate uses an area laser scanner in conjunction with their cobots to further support safety while optimizing production efficiency.

In order for it to be a collaborative application, were limited to a maximum collaborative speed for safety reasons, says Wiegand. In some cases that can be problematic, because were unable to get all the work completed in time with the slower robot travel speeds. In some cases, weve used a safety scanner so that when an operator is not in the area, the robot can run at full speed. When humans come near the robot, it slows down to a safe collaborative speed. The operator can simply touch the robot and it stops.

You can physically just push them out of the way, too. When you restart the robots, they go right back to where they were and carry on with their jobs, he adds.

Wiegand says safety is number one at Flex-N-Gate.

We dot our Is and cross our Ts to ensure that we are in fact integrating these units per the RIA standards and that we are 100 percent safe, he says. We also go a step further and require third-party safety certification.

Proper training for personnel working with and around the new collaborative robots was also a priority.

Traditional robotic safety and avoidance of human-robot interaction is so engrained in our workforce, says Wiegand. Our technicians were sent for collaborative robot-specific training (provided by the robot supplier) and we did safety demonstrations with the plant personnel and operators. It was a bit of a paradigm shift, but it didnt take long for team members to become comfortable working around the collaborative robots.

Ive spent my entire career in automation and robotics, he says. Robots and people occupying the same space has always been a huge no-no. Its cool to see how getting over that hump was surprisingly easy. A lot of it boils down to physically demonstrating that it is, in fact, safe. Showing people something, versus telling them, has a different impact.

Flex-N-Gate has deployed 33 collaborative robots at different facilities throughout the U.S. and Mexico. Worldwide they have approximately 2,000 traditional robots across 62 facilities.

In the last year, weve really gone hard and heavy in the collaborative space, says Wiegand, noting that right now, they primarily use the cobots for vision inspection. As more opportunities present themselves, well continue to look at collaborative robots as a potential solution.

On the West Coast, a different manufacturer was looking to cobots as a potential solution for labor shortages. A robot integrator came to the rescue with two sets of collaborative arms.

Cobot Twins Curb Labor WoesPromotional products supplier iClick had a problem. Their popular PopSockets grips for mobile phones were flying off the shelves, but the Seattle-based company couldnt hire enough workers to keep up with demand. Kitting and bagging product was a tedious job.

Workers were manually attaching the grips to promotional cards and then feeding them one at a time to an automated bagging machine, a labor-intensive process. Even with a crew of four, the workers couldnt keep up with the bagging machine to maximize capacity. Labor continued to be difficult to find and retain.

In an effort to move workers to higher-value jobs, iClick sought out robot integrator House of Design to offer a collaborative robot solution. The FlexBagger system was born.

The robotic kitting and bagging system consists of two ABB YuMi dual-arm collaborative robots. In a carefully choreographed dance of their seven-axis arms, each robot attaches PopSockets to promotional cards and then drops them into the automated bagging machine.

Watch the cobot twins take turns bagging branded PopSockets.

Since each robot must occupy the same space as they deposit assembled items in the bagging area, the timing of the arms needs to be coordinated to avoid collisions. House of Design used ABB RobotStudio to program the robot workstation and ensure smooth movements of its kinematically redundant arms.

Flexible Kitting and BaggingChad Svedin, Project Manager for House of Design in Nampa, Idaho, says the manual bagging process was painstaking. Human workers werent able to put the product in the bags fast enough. With two dual-arm robots working in concert, they can perform the work of four people and keep the automated bagger fully stocked.

Launched in February 2018, this was iClicks first foray into robotics. It was so successful that less than a year later, they ordered another FlexBagger system.

House of Design markets the FlexBagger for other kitting and bagging applications. The YuMi cobot is equipped to grab various small items such as screws, nuts or washers and assemble them in bags. Check out this demo with different sizes and colors of interlocking toy bricks.

Like other power and force limiting cobots, YuMi has special characteristics to help it work collaboratively in close proximity or directly with its human coworkers. It was important to iClick to have a collaborative robot so its workforce could easily enter the robots operating space to remove defective items or replenish products when necessary. The dark gray areas on YuMis arms are padded for safety in the event of contact.

If someone juts their hand into the working system, it bumps into them and freezes in its spot, notes Svedin. A minor bump will stop it from moving.

House of Design trained iClick personnel on safety, and how to run and program the robots.

They loved that the robots looked very humanlike and that they could approach it, says Svedin. It wasnt this thing in a box away from them. They saw it as a part of their crew.

Cobots are part of the crew in unexpected places. Manufacturing isnt the only sector with labor woes. The floral industry is on the verge of a labor crisis and looking to automation for solutions.

Roses and RobotsVisitors to the Automate Show last April may have caught a glimpse of a cobot arranging small bouquets of roses, or you may have even taken home a souvenir bouquet. Some of us skipped the buds for the backstory.

FloraBot is the brainchild of Founder and CEO Alex Frost, a second-generation florist who grew up in his parents retail flower business. For the past dozen years, his Fort Lauderdale, Florida-based software company, QuickFlora, has been providing cloud-based ERP systems for floral retailers.

We work with a lot of retailers in the U.S. and Canada helping them manage their software technology frontend and backend systems. We have a front-row seat to some of their challenges. Over the last 5 to 10 years, there have been fewer and fewer people going into the flower business, so its hard to find qualified floral designers to work in flower shops.

He says you compound that with increasing minimum wage rates in many places such as California, and you have a real labor shortage in the floral industry. Its an environment he thinks is ripe for collaborative robots.

We see them flipping hamburgers, making pancakes and serving coffee. We decided last year, lets bring one of these machines in here and see what it can actually do, says Frost. Can we program it to make flower arrangements? Can we create a turnkey cell for end users?

If you think of Kroger, they have 4,000 stores across the country (marketed under different supermarket brands). Each store needs about 10 to 30 arrangements every day, he says. Those are all made by hand right now. Usually, you have 50 to100 people in a cooler set at 34 degrees. The process is very labor-intensive and you cant scale it. When Valentines Day or Mothers Day comes around and volume increases 5 or 10 times, you cant just hire 5 or 10 times the people that fast when you dont have space. Theres a labor shortage issue, a labor cost issue, and a scalability issue.

Automating Floral DesignFrost sees an emerging market, not only in North America but worldwide. In fact, most of his inquiries come from Western Europe, because labor costs are higher and the European market tends to be more receptive to adopting automation technologies. He notes the evolving niche for precision agriculture, which we examined in Cultivating Robotics and AI for Sustainable Agriculture, where startups and established companies are adapting collaborative robotics for farming.

We sort of fit into that category because were dealing with product that is very sensitive, not heavy, that requires specialized grippers, force control, and vision systems to actually make it work, says Frost. There are a lot of similarities between our technology and that technology in terms of trying to handle delicate flower stems of all shapes and sizes, and then pick and place them into specific xyz coordinates with reasonable cycle time and low defect rate.

He was skeptical himself at first. But as their research and product testing progressed over the last year, he became a believer. They decided to start with a Universal Robots collaborative robot because of their relative ease of use and ease of programming. They have a built-in ecosystem of compatible hardware makers and apps. Theyre also easily portable.

The current FloraBot system uses a UR5 cobot with a Robotiq Hand-E gripper. Previous testing was conducted with grippers from Ubiros and Soft Robotics. Frost says the gripper system has been a big part of the learning process.

What we realized is that nothing worked off the shelf. Absolutely nothing. We had to come up with our own proprietary fingers. Now were working on our own proprietary servo-electric gripper. It will give our end users more flexibility.

Check out this early iteration of the FloraBot system in action on the trade show floor.

FloraBot- The worlds first robotic floral designer by FloraVina from QuickFlora on Vimeo.

Turnkey and Travel-ReadyWhile patents are still pending, FloraBot wont release shots of the near production-ready system. They are currently pilot testing at one company in Miami. They plan to start shipping units in January 2020 right after their official launch at the Consumer Electronics Show (CES).

Frost says the system can assemble AIFD-quality floral arrangements at 100-200 units per hour, 24/7, and with an ROI in less than a year. Right now they plan to sell the system, but eventually, he expects to move to a RaaS model. That way flower companies and growers will be able to try it without making a CapEx investment.

FloraBot supposedly excels at small arrangements about 12 cubic inches. But when you get into larger arrangements like a dozen long-stem roses in a vase, it requires a different kind of gripper. Thats where FloraBot will have to turn to proprietary grippers of their own.

Frost is envisioning a turnkey system they can ship on a 48 in. x 48 in. pallet, basically one robot cell that can do specific tasks within an assembly line. For example, to create an arrangement you may need six cells on the line. One robot that cuts the foam for the container, one that hydrates the foam, one that picks/places the foliage, then one that picks/places the flowers, one that sleeves the arrangement, and another that puts it in the box.

Right now, we see that the machines are capable of doing 75 percent of what humans do in the floral business, whether its a typical flower shop or the mass market, says Frost. Thats really the sweet spot for this technology, the mass market because they crank out high volumes (2000-3000 bouquets) of the same type of arrangements on a daily basis. There will always be a market for people that want something custom. But the reality is most retail florists make the same arrangements week in and week out.

FloraBot has been approached by companies that put flower arrangements in boxes and ship them around the world. There are a lot of new, innovative players in the flower business. Frost says most of the new upstarts are the most receptive to automation.

Weve had requests to do Hawaiian flower leis, which is a very labor-intensive process. Others want us to make different animals covered with roses, which is popular in many countries. Thats also very labor-intensive because you have to cut out a foam model of a little French poodle and then put 600 roses on it. That usually takes 4 to 8 hours. There are definitely cases where machines will take over in terms of production capability.

You might not know that it was created by a robot and you might not care, says Frost. If the customer gets a beautiful flower arrangement that has 12 to 24 stems, the color palette is wonderful and its at their price point, theyre going to be happy. At the end of the day, its about delivering the most value for the customer.

In June, FloraBot exhibited at the International Floriculture Expo (IFE) in Miami, touted as the largest B2B floral event in North America. Frost was astounded by the interest.

Everyone at the flower show, big growers and bouquet makers, came over to the booth and asked how they could use the robot to cut their payroll. No one asked or cared about the technology, or whether it worked or not. It just came down to cost and ROI. CFOs came over. I never had so many C-suite-level people engage in serious discussions at a show. That really tells us were on the right path.

FloraBot recently beat a path all the way to Boston, where they opened a new office at MassRobotics, one of the major robotics clusters. It will be interesting to see what comes next.

Five years from now there will be no humans making flower arrangements, says Frost, because when you see labor savings in the range of 50 to 75 percent, it just doesnt make economic sense anymore.

From rosebuds to electrical connectors, cobots are popping up in industries far and wide.

Mobile Production AssistantCollaborative robots also come in mobile varieties, including this mobile manipulator that integrates an autonomous mobile platform with a six-axis articulating arm. Stubli Electrical Connectors relies on the HelMo mobile robot system from Stubli Robotics to help supplement production during peak demand or during human workforce shortages due to illness or other unforeseen absences.

Once trained, HelMo can handle almost any manual job on the various assembly lines at the connector manufacturers facility in Allschwil, Switzerland. The production assistant navigates to its own workstation, decelerates or stops when human coworkers come too close, and then automatically resumes its operation when the protected workspace is clear.

As soon as HelMo arrives at its workstation, the cobot precisely positions itself within a tenth of a millimeter by referencing three permanent orientation points at the workstation. HelMo then connects itself via a multi-coupling to the fixed supply sockets for electricity and compressed air, then starts its shift.

The mobile cobot is also equipped with an automatic tool change system. One day it could be working with connector housings and contact pins. The next day might be some other stage in the assembly process, wherever its needed.

Integrated atop the mobile platform is a standard Stubli TX2-90L robot with a 15 kg payload and 1,200 mm reach. Watch the HelMo mobile robot system autonomously load rotary tables for manufacturing pneumatic couplings, and later in the footage safely navigate around human coworkers and other equipment in the production space.

The flexible production assistant monitors its environment with three integrated laser scanners. HelMo can perform its tasks automatically or in collaboration with humans.

Material Transport CobotsIn Japan, a fleet of mobile robots collaborates with humans. OMRONs FA sensor manufacturing facility in Ayabe wanted to upgrade its material transport system with a fully automated solution for transporting work-in-progress (WIP) components throughout the factory.

Ayabe is both a production facility and a development facility. In addition to producing OMRON technologies for customers, it also serves as an environment for testing and optimizing new products, including the OMRON LD mobile robot. Moving away from cumbersome conveyor belts that are difficult to rearrange, the engineering team opted for this flexible mobile solution where robots autonomously navigate their way through dynamic environments.

Each LD mobile robot gets its configuration data from the Enterprise Manager, which helps optimize traffic flow by sharing each robots position and trajectory with other robots in its vicinity. This allows each mobile robot to make path adjustments on the fly to avoid people, obstacles and other robots in its path.

The Enterprise Manager allows operators to manage map and configuration updates from a central communication point. These updates are then pushed to each mobile robot in the fleet. The Enterprise Manager also provides a queuing manager to receive job requests from call buttons and automation equipment, and then dispatch jobs to the mobile robots.

In the Ayabe factory, the mobile robots carry product containers between the assembly, final inspection and shipment stations. Since the mobile robot system is connected with the manufacturing engineering system (MES), transportation orders through the MES are conducted according to the work in progress. Watch Ayabes mobile robot fleet in action.

To make transportation more efficient, each LD mobile robot has two lifts, one on the front and one on the back, which makes it possible to carry materials to two destinations in a single trip.

We were able to automate 75 percent of all material transport tasks using these mobile robots, says OMRONs Assistant Manager Makoto Kasuya. People used to move containers in batches, but now robots can move them more frequently. As a result, the lead time needed to transport material has decreased by 80 percent on average.

The overall solution also reduces the expense and effort required for future investments, as LD mobile robots can be easily implemented in other factories without incurring new design costs.

Using its workforce for higher-value tasks instead of moving around products and materials will help Japans manufacturing sector address a growing labor shortage crisis as the countrys population continues its rapid decline. Workers at OMRONs Kusatsu factory used to manually transport up to 300 containers per day. Now the LD mobile fleet does what robots do best, enabling the people to focus on more creative work.

Creativity is still the human element. We need inspiration, ingenuity and vision, the kind that dreams up unique floral designs, innovative tech toys, and adds new functionality and value to age-old automotive components. Robots push us to be better.

RIA Members featured in this article:ABB RoboticsFANUC America CorporationOMRON AutomationStubli North America

Originally published by RIA via http://www.robotics.org on 12/16/2019

Read the original here:
Robotics Industry Insights - Cobots, Raising the Human... - Robotics Online - Robotics Online

Posted in Idaho Stem Cells | Comments Off on Robotics Industry Insights – Cobots, Raising the Human… – Robotics Online – Robotics Online

Aspen Neuro Bags $6.5M to Test Parkinson’s Disease Stem Cell Therapy – Xconomy

Posted: December 16, 2019 at 4:45 am

XconomySan Diego

Nearly nine years ago Jeanne Loring and her colleagues at Scripps Research debuted a test that leveraged advances in genomics and data science to determine, without testing in animals, whether human stem cells were pluripotent, or able to become any type of cell in the body.

Being able to prove that has become increasingly important as scientists look to induced pluripotent stem cells (iPSCs)mature, specialized cells that have been reprogrammed as immature cells, regaining the capability of becoming any type of cellas material for new regenerative medicines.

Now Loring and Andres Bratt-Leal, who joined her lab in 2012 as a post-doctoral researcher, have founded a biotech that combines stem cell biology and genomics know-how to advance a potential cell therapy for Parkinsons disease.

The startup announced Thursday it raised a seed round of $6.5 million to support its work. Aspens lead drug candidate, which is in preclinical testing, is intended to replace neurons in the brains of people with the disease, which causes those cells to become damaged or die.

When people with Parkinsons disease lose neurons, they also lose a chemical messenger the cells produce, called dopamine. Without dopamine, communication between nerve cells falters, which leads to the debilitating motor problems that characterize the disease. Existing Parkinsons drugs aim to alter dopamine levels. Aspen, however, wants to fix the upstream problem that leads to those lowered levels by reconstructing patients damaged neural networks.

The cell therapy would involve harvesting patients own living cells through a skin biopsy, reprogramming them to immature cells, or iPSCs, then further engineering them to become predisposed to mature into neurons. Once enough of those cells have been grown in the lab, those neuron precursor cells would be delivered directly to the brain.

Using a patients own cells avoids the dangerous immune system reactions that can occur when donor cells are used in such therapies, and obviates the need for immunosuppression drugs. Two cell therapies that use genetic engineering have been approved by the FDA, both of which take and tweak patients T cells into treatments for cancer. Stem cell transplants have been used to treat some cancers.

Aspen worked to ensure the company could ably manufacture a so-called autologous replacement cell therapy, or one from a patients one cells, by improving the process of differentiating iPSCs into dopamine neurons, Loring says. And the group developed another predictive genomic-based test, similar to the effort Loring spearheaded nearly a decade ago to determine whether cells were pluripotent, that can detect which iPSCs are destined to become neurons.

(Bratt-Leal) put his biological engineering expertise into coming up with a way that was reproducible, that we would get the same cells no matter who we got the original cells from, she says.

The company plans to test the therapy in patients that they determine, through genomic testing, have the most common form of Parkinsons, which is referred to as sporadic and arises without a clear genetic predisposition. It also has a second treatment in the works that it intends to develop for patients with familial forms of the disease, and uses a gene editing toolyet to be selectedto alter their stem cells during the reprogramming process.

Howard Federoff, who was most recently vice chancellor for health affairs and CEO of the UC Irvine Health system, is Aspens CEO. Federoff says he has come to believe that Parkinsons patients need more than just to stabilize their disease They need to turn the clock back.

Many companies are working on drugs to treat Parkinsons, but most are meant to manage symptoms rather than reverse the disease. Levodopa, which supplants missing dopamine, is used widely, but it can cause side effects, including involuntary movement called dyskinesia; and, as the disease progresses, the drug eventually stops working between doses.

Aspen claims it is the only company working toward an autologous neuron replacement. The company, however, will need to raise a Series A round to move its drug candidates through Phase 2 proof-of-concept trials, Loring says.

The company raised its seed round from a group of investors including Domain Associates, Alexandria Venture Investments, Arch Venture Partners, Axon Ventures, OrbiMed, and Section 32. Initially, it was financed through grants from Summit for Stem Cell, a San Diego-based nonprofit.

Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com.

Continue reading here:
Aspen Neuro Bags $6.5M to Test Parkinson's Disease Stem Cell Therapy - Xconomy

Posted in Stem Cell Treatments | Comments Off on Aspen Neuro Bags $6.5M to Test Parkinson’s Disease Stem Cell Therapy – Xconomy

Bioethics experts call on GoFundMe to ban unproven medical treatments – The Verge

Posted: December 16, 2019 at 4:45 am

A bioethics study published on December 8th calls on crowdfunding platform GoFundMe to ditch campaigns for unproven and unsafe medical procedures.

People turn to GoFundMe for help paying for all sorts of medical interventions. These campaigns have brought in over $650 million since 2010. But a subset of the money raised is spent on unproven and even illegal operations. Unregulated stem cell therapies, for example, attract harsh condemnation from the Food and Drug Administration, and Google even banned ads for the procedures. But the public fundraisers still appear on GoFundMe.

In the new paper, published in the peer-reviewed bioethics journal The Hastings Center Report, the authors argue that GoFundMe enables misinformation that enriches bad actors and can harm patients sick with cancer or other serious conditions. Between November 2017 and November 2018, GoFundMe campaigns raised over $5 million for unregulated neurological stem cell procedures, according to a recent study. Those campaigns were shared over 200,000 times on social media.

They know this is happening. It cant happen without their involvement, says Jeremy Snyder, a bioethics researcher at Simon Fraser University and co-author of the report. I think they should be ashamed of themselves for taking part in it.

This report comes days after The Washington Post reported that an unregulated stem cell treatment center based in Tampa, Florida, openly coached patients to take out loans and crowdfund thousands of dollars for risky procedures.

I think its absolutely beyond time for them to stop, Snyder says about GoFundMes inaction. And an instance of them running counter to what the rest of the tech sector seems to be doing.

Tech companies are facing more scrutiny for enabling clinics that push pseudoscience, and major players like Facebook and Google have taken action. Facebook is removing sensational health claims, and Google recently banned predatory ads for unregulated cell therapies. But GoFundMe has yet to act in a comparable way when it comes to similar treatments.

Alison Bateman-House, an assistant professor at New York Universitys Langone Health and a bioethics expert who is unaffiliated with the report, says its perfectly reasonable to bar unproven treatments from fundraising.

Bateman-House is concerned that GoFundMe allows misinformation, suggesting it messes with patients abilities to make informed decisions by not policing false medical claims. We know that most Americans are not medically literate, she says. Where there is money to be made, some will prey on the hopes and misunderstandings of others.

In response to questions from The Verge, a GoFundMe spokesperson shared a company statement related to its policies on stem cell therapy. The statement says it is reaching out to experts and medical regulatory authorities to understand the effect on their customers, but that ultimately it is up to the GoFundMe community to decide which campaigns to donate to.

Every campaign on GoFundMe whether its for regulated or unregulated treatments is an opportunity for the site to make money. When someone donates to a cause, the platform gives donors an option to add a voluntary tip to the company, which defaults to 10 percent.

The paper, written by Snyder and his co-author, Harvard Law professor I. Glenn Cohen, suggests steps GoFundMe may take to upend its ethical problem. They concede that expecting the platform to independently evaluate evidence for medical claims would be expensive and difficult. Instead, they propose a white list approach, only allowing people to raise money for regulated treatments or those cleared by the FDA for a special program called expanded access.

There may be some challenges to implementing, says Patricia Zettler, a law professor formerly with the FDA who is unaffiliated with the report. But, as they say, we shouldnt let the perfect be the enemy of the good...these are sensible suggestions.

Another option the authors propose is to compile a black list of egregious procedures. They encourage GoFundMe to partner with organizations like the American Cancer Society to create the lists, in addition to the FDA, which frequently sends warning letters to problematic clinics.

In fact, some experts say that one way to avoid these crowdfunding issues would be to not only push platforms to act, but also to give bodies like the FDA more power to regulate them. Were in a moment right now where theres a lot of push to deregulate everything, says Aziza Ahmed, an expert in health law who is not affiliated with the study. I do think we need to press these tech companies to act a lot more ethically, but at the same time we need to do a better job of beefing up the FDA.

GoFundMe has banned campaigns in the past. The site removed anti-vaxxers in March, and it banned fundraising for a high-profile and highly controversial German cancer clinic in July. But many controversial treatments such as LGBTQ conversion therapy and unproven treatments for brain conditions are not yet prohibited by GoFundMe.

I think their first step would be to seek ethical advice, says Cohen. Crowdsourcing platforms could try white or black list approaches, and either would be superior to the status quo free-for-all.

Neither Snyder nor Cohen could predict whether their report will lead to change, but Snyder is certain that change is overdue. I just dont see that GoFundMe can continue to stick their head in the sand and pretend this isnt a problem on this platform.

Go here to read the rest:
Bioethics experts call on GoFundMe to ban unproven medical treatments - The Verge

Posted in Stem Cell Treatments | Comments Off on Bioethics experts call on GoFundMe to ban unproven medical treatments – The Verge

Cutting Edge Exosome Regenerative Therapy Comes to Yelm’s AM Medical – ThurstonTalk

Posted: December 16, 2019 at 4:45 am

When embryonic Stem Cell therapy was first discovered in 1998, it changed the face of medicine. The idea of being able to regenerate and replace damaged cells seemed futuristic at the time, yet today such treatments are commonplace. Now, science has taken another quantum leap this time into the nano-sized world of exosomes, tiny bubbles that grow out of cell walls and contain much of the information contained within the cell including Growth factors, microRNA and messenger RNA. Mesenchymal stem cell (MSC) exosome therapy is currently one of the hottest trends in regenerative medicine, one that patients at AM Medical in Yelm can now experience.

Everyone has heard of stem cell therapy, but it turns out that its not the stem cells that are doing the work, says Dr. Ana Mihalcea, President of AM Medical. Its the exosomes that carry the information of regeneration. Infused stem cells, attach to blood vessel walls, and then give off exosomes.

Exosomes have several key differences from stem cells; they do not get removed from the circulation like stem cells, which are in the body for less than 72 hours before they get destroyed by the immune system; they do not produce a rejection reaction because they are not a cell and contain no DNA, and they pass the blood brain barrier, Mihalcea notes. In a study on stroke scientists fluorescently tagged exosomes, and the infused exosomes went exactly to the region where the stroke had occurred, she adds. The same was not true of stem cells as they do not cross the blood brain barrier.

As a result of their powerful cargo, exosomes can be used to address a multitude of conditions, including arthritis, autoimmune disorders, cardiovascular and neurogenerative diseases like Parkinsons and Alzheimers. Old cells can be reprogrammed by MSC exosomes as the target cells can transcribe the microRNA into functional proteins. Just like a virus, the exosome information of the young stem cells can infect the old cells with Youth, explains Mihalcea.

Spinal cord injuries are an area in which exosomes have produced dramatic results. Mihalcea cites the example of Dr. Douglas J. Spiels Interventional Pain Specialty Practice in NJ. Dr. Spiel has been able to rehabilitate spinal cord injuries with Exosome infusions into the spine and intravenously, she says. After several weeks, hes had patients regain muscle strength and sensation. These are prolonged, ongoing regenerative effects that continued to improve for months after the infusion.

When it comes to autoimmune diseases, inflammation plays a key role. Again, exosomes are able to reduce the problem by downregulating inflammation. TGF Beta 3 [Transforming growth factor beta-3] is the most important anti-inflammatory protein in the body and is abundant in MSC exosomes says Mihalcea. Many more Growth factors for blood vessel growth, neuronal and other tissue growth are present, allowing regenerative effects in all organ systems including skin wounds and burns.

The exosomes at AM Medical come from a laboratory in Florida that conducted pioneering research in the field. They come from perinatal mesenchymal stem cells and are scanned for any possible viruses to ensure their safety. Once harvested, the exosomes are concentrated so they can be infused in large doses.

For patients who qualify, the infusion process takes 10 to 15 minutes. Already, its been producing results for AM Medical patients. Weve had people with arthritis and chronic pain who had great responses, Mihalcea notes. There is an overall increase in wellbeing and sense of rejuvenation that is definitely noticeable.

Perhaps one of the largest sources of excitement over exosomes has to do with their anti-aging effects. Recently, ideas about the root causes of aging have been evolving, according to Mihalcea. Its been thought that aging occurs due to multiple different reasons like stem cell exhaustion, epigenetic changes, telomere shortening and others, she explains. It turns out that exosomes can modify almost all the hallmarks of aging. Theyre changing epigenetic expression to youthful function, and there are many potential applications. This is a new frontier in regenerative medicine that can help many people.

Learn more by watching Dr. Ana Mihalceas video on Exosomes The New Frontier Part 1: Longevity and Age reversal or reading further on the AM Medical website.

Sponsored

More:
Cutting Edge Exosome Regenerative Therapy Comes to Yelm's AM Medical - ThurstonTalk

Posted in Stem Cell Treatments | Comments Off on Cutting Edge Exosome Regenerative Therapy Comes to Yelm’s AM Medical – ThurstonTalk

Stem Cell Therapies Market research Likely to Emerge over a Period of 2015-2025 – PharmiWeb.com

Posted: December 16, 2019 at 4:44 am

VALLEY COTTAGE, N.Y. Stem cells are undifferentiated biological cells, and having remarkable potential to divide into any kind of other cells. When a stem cell divides, each new cell will be a new stem cell or it will be like another cell which is having specific function such as a muscle cell, a red blood cell, brain cell and some other cells.

There are two types of stem cells

Stem cells harvested from umbilical cord blood just after birth. And this cells can be stored in specific conditions. Stem cells also can be harvest from bone marrow, adipose tissue.

Embryonic cells can differentiate into ectoderm, endoderm and mesoderm in developing stage. Stem cells used in the therapies and surgeries for regeneration of organisms or cells, tissues.

Stem cells are used for the treatment of Gastro intestine diseases, Metabolic diseases, Immune system diseases, Central Nervous System diseases, Cardiovascular diseases, Wounds and injuries, Eye diseases, Musculoskeletal disorders.

Download the sample copy of Report with table of contents and Figures @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1087

Harvesting of Adult cell is somewhat difficult compare to embryonic cells. Because Adult cells available in the own body and it is somewhat difficult to harvest.

Stem Cell TherapiesMarket: Drivers and Restraints

Technology advancements in healthcare now curing life threatening diseases and giving promising results. Stem Cell Therapies having so many advantages like regenerating the other cells and body organisms. This is the main driver for this market. These therapies are useful in many life threatening treatments. Increasing the prevalence rate of diseases are driven the Stem Cell Therapies market, it is also driven by increasing technology advancements in healthcare. Technological advancements in healthcare now saving the population from life threatening complications.

Increasing funding from government, private organizations and increasing the Companies focus onStem cell therapiesare also driven this market

However, Collecting the Embryonic Stem cells are easy but Collecting Adult Stem cell or Somatic Stem cells are difficult and also we have to take more precautions for storing the collected stem cells.

Preview Analysis of Stem Cell Therapies Market: Global Industry Analysis and Opportunity Assessment 2015 2025: https://www.futuremarketinsights.com/reports/stem-cell-therapies-market

Stem Cell TherapiesMarket: Segmentation

Stem Cell Therapies are segmented into following types

Based on treatment:

Based on application:

Based on End User:

Stem Cell TherapiesMarket: Overview

With rapid technological advantage in healthcare and its promising results, the use of Stem Cell Therapies will increase and the market is expected to have a double digit growth in the forecast period (2015-2025).

Stem Cell TherapiesMarket: Region- wise Outlook

Depending on geographic regions, the global Stem Cell Therapies market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa.

The use of Stem Cell Therapies is high in North America because it is highly developed region, having good technological advancements in healthcare setup and people are having good awareness about health care. In Asia pacific region china and India also having rapid growth in health care set up. Europe also having good growth in this market.

Buy this report @https://www.futuremarketinsights.com/checkout/1087

Stem Cell TherapiesMarket: Key Players

Some of the key players in this market are

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you:https://www.futuremarketinsights.com/askus/rep-gb-1087

More from Healthcare, Pharmaceuticals and Medical devices:

About Us

Future MarketInsights (FMI) is a leading market intelligence and consulting firm. We deliversyndicated research reports, custom research reports and consulting serviceswhich are personalized in nature. FMI delivers a complete packaged solution,which combines current market intelligence, statistical anecdotes, technologyinputs, valuable growth insights and an aerial view of the competitiveframework and future market trends.

Contact UsMr.Abhishek BudholiyaFuture Market Insights616 Corporate Way, Suite 2-9018,Valley Cottage, NY10989,United StatesT:+1-347-918-3531F: +1-845-579-5705T(UK): + 44-(0)-20-7692-8790Sales:sales@futuremarketinsights.comPress Office:Press@futuremarketinsights.comBlog:MarketResearch BlogWebsite:https://www.futuremarketinsights.com/

Here is the original post:
Stem Cell Therapies Market research Likely to Emerge over a Period of 2015-2025 - PharmiWeb.com

Posted in Stem Cell Treatments | Comments Off on Stem Cell Therapies Market research Likely to Emerge over a Period of 2015-2025 – PharmiWeb.com

Treatment Characteristics and Outcomes for Patients With Rare Forms of T-Cell Lymphoma – Hematology Advisor

Posted: December 16, 2019 at 4:44 am

Researchers evaluated treatment characteristics and outcomes of 3 rare subtypes of T-cell lymphoma, and their findings were published in the American Journal of Hematology.

The prospective study assessed treatments and clinical outcomes for patients with enteropathy-associated T-cell lymphoma (EATL), hepatosplenic T-cell lymphoma (HSTCL), and peripheral gamma delta T-cell lymphoma (PGDTCL). Patient cases were identified from the T Cell Project (ClinicalTrials.gov Identifier: NCT01142674) database, and therapies were guided by treating physicians.

Among 1553 eligible patient cases, a total of 65 patients (4.2%) were diagnosed with EATL, 31 (2%) with HSTCL, and 19 (1.2%) with PGDTCL.

Median study follow-up was 77 months for patients with PGDTCL, 64 months for patients with HSTCL, and 32 months for patients with EATL.

The 5-year overall survival (OS) rates were 30% with EATL, 40% with HSTCL, and 51% with PGDTCL. Median progression-free survival (PFS) was shortest for patients with EATL, at 7 months (95% CI, 4-10). For patients with HSTCL, median PFS was 11 months (95% CI, 8-14), and for patients with PGDTCL, median PFS was 14 months (95% CI, 6-21).

Treatment data were evaluable for 93 patients. All evaluable patients with PGDTCL and 97% of those with EATL received anthracycline-based therapies, compared with 60% of evaluable patients with HSCTL. Complete response rates to initial chemotherapy regimens were 30% for EATL, 40% for HSCTL, and 25% for PGDTCL. Autologous stem cell transplantation was used during first remission in a minority of patients with each of the 3 subtypes of T-cell lymphoma.

The study investigators highlighted the value of registries in studies of rare diseases. In the case of this study, the investigators noted a lack of standardized treatment practices for the examined T-cell lymphoma subtypes, and they recommended that patients with rare T-cell lymphoma subtypes be included in studies of novel agents.

Reference

Here is the original post:
Treatment Characteristics and Outcomes for Patients With Rare Forms of T-Cell Lymphoma - Hematology Advisor

Posted in Stem Cell Treatments | Comments Off on Treatment Characteristics and Outcomes for Patients With Rare Forms of T-Cell Lymphoma – Hematology Advisor

CAMPUS: EGG DONATION – Artificial sperm cells to remove the genetic worries of sperm donation – ESHRE

Posted: December 16, 2019 at 4:44 am

A Campus meeting in November reviewed the arguments for and against donor conception, and the sometimes difficult ethical arguments raised by the prospect of a donor-conceived child. 'Artificial' sperm cells derived from testicular tissue or stem cells may resolve some of those arguments.

The problem is especially acute in cancers diagnosed in prepubertal boys in whom there are no sperm cells available for storage. Their only option for future fatherhood in the face of cancer treatment is adoption or donor sperm. And this, added Goossens, is not an exceptional problem. Incidence rates are around 17 cases per 100,000 population, with leukemia and CNS tumours the most commonly diagnosed. So the usual pathway to fertility preservation in these young cases is for the oncologist to warn of the risk to future fertility from the cancer treatments and refer to the fertility clinic. Biopsy of testicular tissue, of course, must be performed before any radio- or chemotherapy.

Goossens described two experimental techniques, spermatogonial stem cell retrieval and transplantation, and homotopic tissue grafting. The danger in the former procedure is a risk of introducing malignancy, so banked tissue must be free of malignant contamination. Experiments in mouse-to-mouse models have demonstrated spermatogenesis from tissue grafting, and most recently fully functional conception and delivery in a non-human primate (Grady). Similarly, experiments in mouse models with spermatogonial stem cell transplantation have so far proved efficient, with spontaneous pregnancy already possible.

Of course, the objective of this impressive experimental work is not merely a resolution to the question of genetic continuity in couples faced with third-party donation, but the future fertility and long-term quality of life of so many unfortunate young boys. Advances in cancer treatment have led to the increased survival of all children with cancer, and with it a new imperative for the restoration of their fertility. Not all cancer treatments cause complete testicular damage, but around one-third of children having treatment for pediatric cancers will end up infertile. Following the proof-of-concept study which saw the birth of Grady - in which testicular samples removed from prepubertal monkeys was frozen, thawed and regrafted under scrotal skin - the research group declared that their next logical step, with safety and feasibility apparent, is human trials.

1. Fayomi AP, Peters K, Sukhwani M, et al. Autologous grafting of cryopreserved prepubertal rhesus testis produces sperm and offspring. Science 2019; 363: 1314-1319.

Visit link:
CAMPUS: EGG DONATION - Artificial sperm cells to remove the genetic worries of sperm donation - ESHRE

Posted in Stem Cell Treatments | Comments Off on CAMPUS: EGG DONATION – Artificial sperm cells to remove the genetic worries of sperm donation – ESHRE

Promethera Attracts Sony Innovation Fund by IGV and Pegasus Tech Ventures as New Investors in Final Closing of Series D – BioSpace

Posted: December 16, 2019 at 4:44 am

Total amount raised in the Series D reaches 47.2 Million

MONT-SAINT-GUIBERT, Belgium and TOKYO, Dec. 16, 2019 /PRNewswire/ -- Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the addition of 7.5 million to its recent 39.7 million Series D financing led by new investors Sony Innovation Fund by IGV and Pegasus Tech Ventures. MEDIPAL Holdings, the family office Six Snow, a Japanese private investor and a Belgian private investor also contributed to the extension. Promethera will use the proceeds from the financing to further advance the company's clinical programs in Non-alcoholic steatohepatitis (NASH) and Acute-on-Chronic Liver Failure (ACLF), as well as to accelerate Promethera's growth in the Asian markets. The company plans to initiate clinical trials outside Europe in its two lead indications, NASH and ACLF, during the course of 2020.

"The additional investment by Sony Innovation Fund by IGV and Pegasus Tech Ventures continues to acknowledge the potential of our HepaStem technology," said John Tchelingerian, PhD, President and Chief Executive Officer of the Promethera Group. "With the additional funds provided by the Series D expansion, Promethera plans to further solidify its position as the leading drug development organization in cell-based therapies and regenerative medicines targeting severe liver disorders."

Mr. Gen Tsuchikawa, CEO at Innovation Growth Ventures (IGV) added, "We decided to invest in Promethera due to the company's track record, their global presence, and their promising development programs in areas with significant unmet medical need. Promethera's management has steadily advanced the company's capabilities in stem cell therapeutics for liver diseases and we are happy to invest during this stage of impressive growth."

Over the course of the past 18 months, Promethera has established a rapidly growing organization in Japan with a local branch office in Tokyo that acts as a cornerstone for the company's expansion strategy in Asia. Through a series of financing transactions, Promethera has attracted a number of domestic institutional investors in Asia such as Mitsui & Co. Global Investment, Mitsubishi UFJ Capital Co., Ltd., Shinsei Corporate Investment, Cell Innovation Partners, Shinsei Capital Partners, Korea Investment Partners, Mirae Asset Capital, Beyond Next Ventures, Ci:z Investment LLP and Co-High/CMBCC. The investor base is further complemented by a group of renowned European venture capital firms and family offices as well as strategic investors and corporate venture companies, namely ITOCHU Corporation, Shibuya Corporation, LifeLiver, Sosei Corporate Venture Capital and MEDIPAL HOLDINGS CORPORATION.

About HepaStemHepaStem consists of liver derived stem cells that are obtained from ethically donated healthy human organs and expanded in GMP culture conditions. Updated clinical data from the ongoing phase 2a study (HEP101) in patients with Acute-on-Chronic Liver Failure (ACLF) or Acute Decompensation (AD) at high risk of developing ACLF have been presented in an oral presentation at the Annual Meeting of the American Association for Study of Liver Diseases (AASLD) on November 10, 2019, in Boston, by Promethera's principal investigator Prof. F. Nevens, KULeuven, Belgium. The data set confirmed earlier findings presented at The International Liver Congress - ILC 2019 in April.

A first clinical trial in NASH was initiated H1 2019. In addition to its cell-based approaches, Promethera is advancing a portfolio of complementary biologics approaches including the anti-TNF-R1 antibody Atrosimab.

About Sony Innovation Fund by IGVSony Innovation Fund by IGV is one of the Sony Group's venture investment programs. Sony Corporation and Daiwa Capital Holdings established Innovation Growth Ventures Corporation as part of this program. This venture capital fund was launched in June 2019 by recruiting investors from among both Sony and Daiwa's group companies in addition to external investors.

About Pegasus Tech VenturesPegasus Tech Ventures, headquartered in Silicon Valley, is a venture capital firm that has invested in over 160 startups in the world, including Sofi, 23andMe, Vicarious, x.ai, Color Genomics, Affectiva in US and its Japan portfolio includes post IPO companies such as ZUU, AI CROSS, Geniee, Money Forward, Evolable Asia, Metaps, and DLE, as well as Terra Motors, UniFa, Monstar Lab, Star Festival, Life is Tech, Modalis, and FiNC Technologies. Pegasus invests in companies with the objective of creating financial value and creating strategic value for the firm's investors and portfolio companies. For more information, please visit http://www.pegasustechventures.com.

About Promethera Biosciences Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the antiTNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert, Belgium, Durham, NC, USA, Tokyo, Japan and Basel, Switzerland.

PROMETHERA, HepaStem, H2Stem, are registered trademarks or trademarks of PROMETHERA in the Benelux, the United States and other countries.

View original content:http://www.prnewswire.com/news-releases/promethera-attracts-sony-innovation-fund-by-igv-and-pegasus-tech-ventures-as-new-investors-in-final-closing-of-series-d-300974484.html

SOURCE Sony Innovation Fund

Read more:
Promethera Attracts Sony Innovation Fund by IGV and Pegasus Tech Ventures as New Investors in Final Closing of Series D - BioSpace

Posted in Stem Cell Treatments | Comments Off on Promethera Attracts Sony Innovation Fund by IGV and Pegasus Tech Ventures as New Investors in Final Closing of Series D – BioSpace

Salarius Pharmaceuticals to Present Trial-in-Progress Poster at Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic -…

Posted: December 15, 2019 at 2:49 am

HOUSTON, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, announced today the acceptance of an abstract at the Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic taking place Monday, December 16, 2019 at the Franklin Institute in Philadelphia, PA. The trial-in-progress poster presentation will include an overview of the ongoing Phase 1/2 clinical trial for Salarius lead drug candidate, Seclidemstat, a potent reversible LSD1 inhibitor being developed as a treatment for Ewing sarcoma, a rare pediatric bone cancer.

Details of the symposium and poster presentation are as follows:

Abstract Title: Trials in progress: A phase I/II clinical trial of the reversible LSD1 inhibitor, seclidemstat, in patients with relapsed/refractory Ewing sarcomaWhere: The Franklin Institute, 222 North 20th Street, PhiladelphiaWhen: Monday, December 16, 2019 at 8:30 a.m. EST to 7 p.m. ESTSymposium Website: Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic

The Epigenetics Symposium is an ideal event to showcase our progress bringing our lead drug candidate, Seclidemstat, into the clinic and the impact it could have on Ewing sarcoma, a rare and deadly bone cancer that most often strikes children and young adults and for which there are no targeted therapies approved, stated David Arthur, Chief Executive Officer of Salarius Pharmaceuticals. Lysine demethylase enzymes are a well-known target for epigenetic-based drug development. We have developed Seclidemstat to be a differentiated LSD1 inhibitor, and we are excited that it has reached the clinical trial setting where its safety and therapeutic activity can be assessed. Research shows that LSD1 expression is elevated in 60% of Ewing sarcoma patients and correlates with poor patient prognosis and decreased overall survival. Given the potential of Seclidemstat to address this great unmet need, we look forward to releasing early cohort data next year from our Ewing sarcoma study and a Phase 1 study in advanced solid tumors.

About Salarius PharmaceuticalsSalarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. Epigenetics refers to the regulatory system that affects gene expression. In some cancers, epigenetic regulators often become dysregulated and incorrectly turn genes on or off leading to cancer progression. Drugs that can safely modify the activity of these epigenetic regulators may correct the gene changes that are driving the disease. The companys lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Rare Pediatric Disease designation by the U.S. Food and Drug Administration. Salarius believes that Seclidemstat is one of only two reversible inhibitors of the epigenetic modulator LSD1 currently in human trials, and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies. Salarius is also developing Seclidemstat for several cancers with high unmet medical need, with a second Phase 1 clinical study in advanced solid tumors, including prostate, breast and ovarian cancers. Salarius receives financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as will, can, could, believe, plan, allow, expect, provide, able to, position, anticipate, progress, potential, and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements regarding: the progress in bringing Seclidemstat into the clinic and the impact it could have on Ewing sarcoma; the development of Seclidemstat to be a differentiated LSD1 inhibitor; the potential of Seclidemstat; anticipated timing of release of early cohort data from the companys Ewing sarcoma study and a Phase 1 study in advanced solid tumors; the companys belief that Seclidemstat is one of only two reversible inhibitors of LSD1 currently in human trials and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies; and the companys development of Seclidemstat for several cancers with high unmet medical need, including prostate, breast and ovarian cancers. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the ability of the company to raise additional capital to meet the companys business operational needs and to achieve its business objectives and strategy; the companys ability to project future capital needs and cash utilization; available sources of cash, including from CPRIT and its equity line; future clinical trial results; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of Salarius intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions which may impact the ability of Salarius to access capital under its equity line; the possibility of unexpected expenses or other uses of Salarius cash resources; and other risks described in Salarius filings with the Securities and Exchange Commission, including those under the heading Risk Factors. The forward-looking statements contained in this press release speak only as of the date of this press release and are based on managements assumptions and estimates as of such date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

Contacts Investor Relations LifeSci Advisors, LLCJeremy FefferManaging Director(212) 915-2568 jeremy@lifesciadvisors.com

Media Relations: Tiberend Strategic Advisors, Inc.Johanna BennettSenior Vice President (212) 375-2686 jbennett@tiberend.com

Go here to read the rest:
Salarius Pharmaceuticals to Present Trial-in-Progress Poster at Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic -...

Posted in Epigenetics | Comments Off on Salarius Pharmaceuticals to Present Trial-in-Progress Poster at Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic -…

Page 1,228«..1020..1,2271,2281,2291,230..1,2401,250..»